Table 2 The surgico-pathological characters and treatment-related variables of EOC patients with or without EM
NON-EAOC | EAOC | P | |
|---|---|---|---|
FIGO Stagea | <.0001* | ||
I | 92 (39.15%) | 49 (71.01%) | |
II | 32 (13.62%) | 12 (17.39%) | |
III | 97 (41.28%) | 7 (10.14%) | |
IV | 14 (5.96%) | 1 (1.45%) | |
Early or late Stage | <.0001* | ||
I + II | 124 (52.77%) | 61 (88.41%) | |
III + IV | 111 (47.23%) | 8 (11.59%) | |
Lymphadenectomy | 0.0160* | ||
Yes | 189 (80.43%) | 64 (92.75%) | |
No | 46 (19.57%) | 5 (7.25%) | |
Residual disease | 0.0002* | ||
No or <1 cm | 167 (71.06%) | 64 (92.75%) | |
> 1 cm | 68 (28.94%) | 5 (7.25%) | |
Metastasis of lymph node | 0.0060* | ||
Yes | 35 (14.89%) | 5 (7.25%) | |
No | 154 (65.53%) | 59 (85.51%) | |
Not-dissected | 46 (19.57%) | 5 (7.25%) | |
Histotype | 0.0041* | ||
Clear cell | 81 (34.47%) | 37 (53.62%) | |
Endometrioid | 154 (65.53%) | 32 (46.38%) | |
Endometrial disorders | 0.0808* | ||
Yes | 45 (19.15%) | 7 (10.14%) | |
No | 190 (80.85%) | 62 (89.86%) | |
Endometrial cancer | 0.051 | ||
Yes | 25 (23.8%) | 2 (7.4%) | |
No | 211 (76.2%) | 66 (92.6%) | |
Chemotherapy | 0.6250 | ||
Platinum-based | 224 (95.32%) | 67 (97.1%) | |
Other regimen | 3 (1.28%) | 0 (0%) | |
No chemotherapy | 8 (3.4%) | 2 (2.9%) | |
Chemo Cycles | 6.36 ± 2.33 | 5.70 ± 2.05 | 0.039* |
Chemo-resistance | 0.0149* | ||
Yes | 47 (20%) | 5 (7.35%) | |
No | 188 (80%) | 63 (92.65%) |